In part 2 of my Neuroscience episodes about antidepressants I’m diving into the Glutamate Hypothesis.

I chat about the role of the glutamatergic system within the brain in helping us to better understand why some people don’t respond well to the first line of treatments, such as SSRIs.

I’m also diving into treatment resistant depression, electro convulsive therapy (ECT) neuroplasticity and transcranial magnetic stimulation.

LINKS:

Listen to Part 1 of this series The Neuroscience of Anti-Depressants: The Monoamine Hypothesis at https://pod.fo/e/21783a .
Read the paper ‘Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization’ accessible via PUBMED https://tr.ee/glutamatergic-paper .
Listen to episode 50. Stress on the brain and how to reverse its effects at https://pod.fo/e/1f8306 .
Listen to episode 257 my episode on Ketamine as a treatment for depression here https://bit.ly/Dyfm-ketamine.
Join the DYFM Facebook Group https://bit.ly/dyfm-group .
Follow @dyfmpodcast on IG
Follow @alexispredez on IG
Follow @listnrentertainment on IG

CREDITS

Host: Alexis Fernandez
Executive Producer & Editor: Elise Cooper
Digital Producer: Zoe Panaretos
DYFM Social Producer: Shania Magua
Managing Producer: Sam Cavanagh

Find more great podcasts like this at www.listnr.com/

See omnystudio.com/listener for privacy information.

Dan Rattiner speaks with pioneering fashion designer Liz Lange – Episode 160

Who’s Here in the Hamptons

Introduction

The AI-powered Podcast Player